-transparent.png){kind=logo}
Gene and cell therapies of cardiac arrhythmias are nascent fields whose raison d'etre derives from (1) the problematic state of arrhythmia treatment today (especially atrial and ventricular tachyarrhythmias for which drugs, devices and ablation remain more stopgaps then optimal interventions), and (2) the opportunity to learn and potentially treat and cure by exploring new technologies. The state of antiarrhythmic therapy and new directions being taken are reviewed.
| UI | MeSH Term | Description | Entries |
|---|
Related Publications
Michael R Rosen, and
Peter Danilo, and
Richard B Robinson
June 1983,
Australian and New Zealand journal of medicine,
Michael R Rosen, and
Peter Danilo, and
Richard B Robinson
June 2021,
Deutsche medizinische Wochenschrift (1946),
Michael R Rosen, and
Peter Danilo, and
Richard B Robinson
August 2000,
Resuscitation,
Michael R Rosen, and
Peter Danilo, and
Richard B Robinson
October 2020,
Clinical therapeutics,
Michael R Rosen, and
Peter Danilo, and
Richard B Robinson
March 2005,
Der Internist,
Michael R Rosen, and
Peter Danilo, and
Richard B Robinson
January 1981,
Cardiovascular clinics,
Michael R Rosen, and
Peter Danilo, and
Richard B Robinson
May 1989,
Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde,
Michael R Rosen, and
Peter Danilo, and
Richard B Robinson
November 1987,
American heart journal,
Michael R Rosen, and
Peter Danilo, and
Richard B Robinson
March 2003,
MMW Fortschritte der Medizin,
Michael R Rosen, and
Peter Danilo, and
Richard B Robinson
January 2024,
Pharmacology & therapeutics,
